Clinical Trial Update: Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma [Phase 2]

View source ↗

Summary

Phase 2 study of ipilimumab in children and adolescents with unresectable or metastatic malignant melanoma was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Malignant Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2017-08-01